Limited amounts of dendritic cells migrate into thet-cell area of lymph nodes but have high immune activating potential in melanoma patients

Clinical Cancer Research

Volumn 15, Issue 7, 2009, Pages 2531-2540

  Verdijk, Pauline ^a   Aarntzen, Erik H J G ^a   Lesterhuis, W Joost ^a   Boullart, A C Inge ^a   Kok, Ellemieke ^a   Van Rossum, Michelle M ^a   Strijk, Simon ^a   Eijckeler, Femke ^a   Bonenkamp, Johannes J ^a   Jacobs, Joannes F M ^a   Blokx, Willeke ^a   Vankrieken, Han J M ^a   Joosten, Irma ^a   Boerman, Otto C ^a   Oyen, Wim J G ^a   Adema, Gosse ^a   Punt, Cornelis J A ^a   Figdor, Carl G ^a   De Vries, I Jolanda M ^a,b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DENDRITIC CELL VACCINE; INDIUM 111; SUPERPARAMAGNETIC IRON OXIDE;

ARTICLE; CANCER IMMUNOTHERAPY; CELL MIGRATION; CONTROLLED STUDY; DENDRITIC CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; LYMPH NODE DISSECTION; MELANOMA; PRIORITY JOURNAL; T LYMPHOCYTE;

CANCER VACCINES; CELL MOVEMENT; DENDRITIC CELLS; HUMANS; INJECTIONS; LYMPH NODES; LYMPHOCYTE ACTIVATION; MELANOMA; PHAGOCYTOSIS; SKIN NEOPLASMS; T-LYMPHOCYTES;

EID: 65249088470     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-2729     Document Type: Article

References (31)

1. Figdor CG, deVries IJ, Lesterhuis WJ, Melief CJ. Dendritic cell immunotherapy: mapping the way. Nat Med 2004;10:475-80.
2. Nencioni A, Grunebach F, Schmidt SM, et al. The use of dendritic cells in cancer immunotherapy. Crit Rev Oncol Hematol 2008;65:191 -9.
3. Lesterhuis WJ, Aarntzen EH, deVries IJ, et al. Dendritic cell vaccines in melanoma: from promise to proof? Crit Rev Oncol Hematol 2008;66:118-34.
4. Eggert AA, Schreurs MW, Boerman OC, et al. Biodis- tribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration. Cancer Res 1999;59:3340-5.
5. Okada N, Tsujino M, Hagiwara Y, et al. Administration route-dependent vaccine efficiency of murine dendrit- ic cells pulsed with antigens. Br J Cancer 2001;84: 1564-70.
6. Mullins DW, Sheasley SL, Ream RM, BullockTN, Fu YX, Engelhard VH. Route of immunization with pep- tide-pulsed dendritic cells controls the distribution of memory and effector Tcells in lymphoid tissues and determines the pattern of regional tumor control. J Exp Med 2003;198:1023 -34.
7. Dudda JC, Simon JC, Martin S. Dendritic cell immunization route determines CD8+ Tcell trafficking to inflamed skin: role for tissue microenvironment and dendritic cells in establishment of T cell-homing subsets. J Immunol 2004;172:857-63.
8. Mora JR, Bono MR, Manjunath N, et al. Selective imprinting of gut-homingT cells by Peyer's patch dendritic cells. Nature 2003;424:88-93.
9. de Vries IJ, Krooshoop DJ, Scharenborg NM, et al. Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res 2003; 63:12 -7.
10. Morse MA, Coleman RE, Akabani G, Niehaus N, Coleman D, Lyerly HK. Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res 1999;59:56-8.
11. Quillien V, Moisan A, Carsin A, et al. Biodistribution of radiolabelled human dendritic cells injected by various routes. Eur J Nucl Med Mol Imaging 2005;32: 731 -41.
12. Ridolfi R, Riccobon A, Galassi R, et al. Evaluation of in vivo labelled dendritic cell migration in cancer patients. J Transl Med 2004;2:27.
13. Blocklet D, Toungouz M, Kiss R, et al. 111In-oxine and 99mTc-HMPAO labelling of antigen-loaded dendritic cells: in vivo imaging and influence on motility and actin content. Eur J Nucl Med Mol Imaging 2003;30:440-7.
14. Nair S, McLaughlin C, Weizer A, et al. Injection of immature dendritic cells into adjuvant-treated skin obviates the need for ex vivo maturation. J Immunol 2003;171:6275-82.
15. Thompson M, Wall DM, Hicks RJ, Prince HM. In vivo tracking for cell therapies. Q J Nucl Med Mol Imaging 2005;49:339 -48.
16. Trakatelli M, Toungouz M, Blocklet D, et al. A new dendritic cell vaccine generated with interleukin-3 and interferon-β induces CD8+ Tcell responses against NA17-2 tumor peptide in melanoma patients. Cancer Immunol Immunother 2006;55:469 -74.
17. de Vries IJ, Lesterhuis WJ, Barentsz JO, et al. Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat Biotechnol 2005;23:1407-13.
18. Mackensen A, KrauseT, Blum U, Uhrmeister P, Mer- telsmann R, Lindemann A. Homing of intravenously and intralymphatically injected human dendritic cells generated in vitro from CD34+ hematopoietic progenitor cells. Cancer Immunol Immunother 1999;48: 118-22.
19. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19:3635 -48.
20. de Vries IJ, Eggert AA, Scharenborg NM, et al. Phenotypical and functional characterization of clinical grade dendritic cells. J Immunother 2002;25: 429 -38.
21. Thurner B, Haendle I, Roder C, et al.Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 1999;190:1669 -78.
22. Holtl L, Rieser C, Papesh C, et al. Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells. J Urol 1999;161:777 -82.
23. Vakkila J, Lotze MT, Riga C, Jaffe R. A basis for distinguishing cultured dendritic cells and macrophages in cytospins and fixed sections. Pediatr Dev Pathol 2005;8:43-51.
24. deVries IJ, Bernsen MR, Lesterhuis WJ, et al. Immu- nomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome. J Clin Oncol 2005;23:5779-87.
25. Verreck FA, de BoerT, Langenberg DM, van der ZL, Ottenhoff TH. Phenotypic and functional profiling of human proinflammatory type-1 and anti-inflammatory type-2 macrophages in response to microbial antigens and IFN-γ- and CD40L-mediated costimulation. J Leukoc Biol 2006;79:285-93.
26. Savage ND, de Boer T, Walburg KV, et al. Human anti-inflammatory macrophages induce Foxp3+ GITR + CD25+ regulatory T cells, which suppress via membrane-bound TGFβ-1. J Immunol 2008;181:2220-6.
27. Schnurr M, Chen Q, Shin A, et al. Tumor antigen processing and presentation depend critically on den- driticcell type and the mode of antigen delivery. Blood 2005;105:2465-72.
28. Allan RS, Waithman J, Bedoui S, et al. Migratory dendritic cells transfer antigen to a lymph node-resi- dent dendritic cell population for efficient CTL priming. Immunity 2006;25:153-62.
29. Kleindienst P, Brocker T. Endogenous dendritic cells are required for amplification of T cell responses induced by dendritic cell vaccines in vivo. J Immunol 2003;170:2817-23.
30. Verdijk P, Aarntzen EH, Punt CJ, deVries IJ, Figdor CG. Maximizing dendritic cell migration for cancer immunotherapy. E xpert Opin Biol Ther 2008;8: 865-74.
31. Boullart ACI, Aarntzen EH,Verdijk P,et al. Maturation of monocyte-derived dendritic cells with Toll-like receptor 3 and 7/8 ligands combined with prostaglandin E2 results in high interleukin-12 production and cell migration. Cancer Immunol Immunother 2008;57: 1589-97.